The Klinique Medical Clinic PCL (BKK:KLINIQ) Research & Development: ฿0 Mil (TTM As of Mar. 2026)


BKK:KLINIQ The Klinique Medical Clinic PCL BKK:KLINIQ
88 GF Score
Price ฿25.75
GF Value ฿44.60
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is The Klinique Medical Clinic PCL Research & Development?

The Klinique Medical Clinic PCL BKK:KLINIQ 88 Research & Development is ฿0 Mil as of Mar. 2026. GuruFocus rates BKK:KLINIQ with a GF Score™ of 88/100 and a GF Value™ of ฿44.60 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. The Klinique Medical Clinic PCL's Research & Development for the three months ended in Mar. 2026 was ฿0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ฿0 Mil.

The Klinique Medical Clinic PCL  (BKK:KLINIQ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

The Klinique Medical Clinic PCL Research & Development Related Terms

The Klinique Medical Clinic PCL Research & Development Historical Data

* Premium members only.

The historical data trend for The Klinique Medical Clinic PCL's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Klinique Medical Clinic PCL Research & Development Chart

The Klinique Medical Clinic PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

The Klinique Medical Clinic PCL Quarterly Data
Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BKK:KLINIQ
88GF Score
The Klinique Medical Clinic PCL BKK:KLINIQ
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The Klinique Medical Clinic PCL Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ฿0 Mil mean?
The Klinique Medical Clinic PCL (BKK:KLINIQ) has a Research & Development of ฿0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on The Klinique Medical Clinic PCL and its competitors.
Is The Klinique Medical Clinic PCL's Research & Development too high?
The Klinique Medical Clinic PCL's current Research & Development is ฿0 Mil. Overall, The Klinique Medical Clinic PCL has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Klinique Medical Clinic PCL's Research & Development compare to ROL and SCI?
The Klinique Medical Clinic PCL's Research & Development of ฿0 Mil can be compared against companies in the Personal Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Personal Services company?
A good Research & Development depends on the Personal Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on The Klinique Medical Clinic PCL and its competitors. The Klinique Medical Clinic PCL's current Research & Development is ฿0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Klinique Medical Clinic PCL stock overvalued right now?
Based on GuruFocus' analysis, The Klinique Medical Clinic PCL (BKK:KLINIQ) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿44.60, compared to a current price of ฿25.75 — trading 42.3% below its estimated fair value. The current Research & Development is ฿0 Mil. The Klinique Medical Clinic PCL's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For The Klinique Medical Clinic PCL (BKK:KLINIQ), the current Research & Development is ฿0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is The Klinique Medical Clinic PCL (BKK:KLINIQ) Overvalued in 2026?

Based on GuruFocus' analysis, The Klinique Medical Clinic PCL stock appears to be undervalued. The current stock price of ฿25.75 is trading 42.3% below its estimated GF Value™ of ฿44.60. GuruFocus considers The Klinique Medical Clinic PCL to be Significantly Undervalued.

Key valuation signals for BKK:KLINIQ:

  • Research & Development: ฿0 Mil
  • GF Value™: ฿44.60 vs. price of ฿25.75 (42.3% below fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the BKK:KLINIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

The Klinique Medical Clinic PCL Business Description

Address New Petchburi Road, 2922/296-299, Charn Issara Tower 2, 27th Floor, Bangkapi, Huay Kwang, Bangkok, THA, 10310
The Klinique Medical Clinic PCL provides skin care services, beauty, skin care, body contouring, and surgery. including providing holistic care services. The company has a wide range of services and products to meet the needs of customers at all levels, such as facial treatment services, reducing redness, reducing dark spots, laser services for face lifting, face reshaping, skin care, Body shape by removing and dissolving fat, cosmetic surgery, etc. In addition, the company also sells cosmeceuticals. There are various types of products, such as Special Care, Clean & Prepare, Whitening Set, Sun Care, and Antioxidant. The group operates two core business segments: Skin medical services and distribution of cosmetics and medical cosmetics; and Surgery services.
88GF Score

Get the complete analysis for BKK:KLINIQ

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿25.75
Price
฿44.60
GF Value